The FDA has classified the recall of certain Medtronic Bravo CF Esophageal pH Monitoring Capsules as a Class I recall, the most serious type. The problem arose during manufacturing where the adhesive on the capsule delivery device was improperly applied so that the capsule may not adhere to the esophageal wall or may detach improperly from the delivery device.[4] This creates the risk of capsule inhalation, airway obstruction, esophageal perforation, bleeding, esophageal wall injury, presence of a foreign body in the body, and delay in diagnosis.[4][5] Medtronic reported 33 serious injuries associated with the problem, but no deaths.[4][5] The Bravo system is used to temporarily attach a small pH capsule to the lining of the esophagus, which measures acidity (pH) and transmits the data wirelessly to a recorder on the patient's waist to help diagnose reflux disease.[4][5] Medtronic and its subsidiary Given Imaging sent out two letters to affected customers recommending that specific Bravo CF delivery devices be identified, removed from use, and returned.[4][5] The FDA originally issued an early warning on 6/24/2025 and updated the information on 1/5/2026 to say it was a Class I recall.[4]